Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Protein Page:
CUEDC2 (human)
p Phosphorylation
a Acetylation
m Methylation
m1 Mono-methylation
m2 Di-methylation
m3 Tri-methylation
u Ubiquitination
s Sumoylation
n Neddylation
gl O-GlcNAc
ga O-GalNAc
h Palmitoylation
ad Adenylylation
sn S-Nitrosylation
ca Caspase cleavage

Overview
CUEDC2 Down-regulates ESR1 protein levels through the ubiquitination-proteasome pathway, regardless of the presence of 17 beta-estradiol. Also involved in 17 beta-estradiol-induced ESR1 degradation. Controls PGR protein levels through a similar mechanism. May predict the clinical outcome of tamoxifen therapy of breast cancer patients. Patients with tumors that highly express CUEDC2 do not respond to tamoxifen treatment as effectively as those with tumors with low expression. Belongs to the CUEDC2 family. Note: This description may include information from UniProtKB.
Cellular Component: nuclear membrane; cytoplasm; nucleolus; nucleus
Molecular Function: protein binding
Reference #:  Q9H467 (UniProtKB)
Alt. Names/Synonyms: bA18I14.5; C10orf66; CUE domain containing 2; CUE domain-containing protein 2; CUED2; CUEDC2; MGC2491
Gene Symbols: CUEDC2
Molecular weight: 32,009 Da
Basal Isoelectric point: 4.74  Predict pI for various phosphorylation states
Protein-Specific Antibodies or siRNAs from Cell Signaling Technology® Total Proteins
Select Structure to View Below

CUEDC2

Protein Structure Not Found.


STRING  |  Scansite  |  Phospho.ELM  |  Pfam  |  Source  |  GeneCards  |  UniProtKB  |  Entrez-Gene  |  GenPept  |  Ensembl Gene


Modification Sites and Domains Show Modification Legend
Click here to view phosphorylation modifications only

Modification Sites in Parent Protein, Orthologs, and Isoforms Show Modification Legend
 

Show Multiple Sequence Alignment


 SS 

SS: The number of records in which this modification site was determined using site-specific methods. SS methods include amino acid sequencing, site-directed mutagenesis, modification site-specific antibodies, specific MS strategies, etc.


 MS 

MS: The number of records in which this modification site was assigned using ONLY proteomic discovery-mode mass spectrometry.


       human

 
0 1 K82-u TIGDMMQkLSGQLSD
1 2 S110-p VQGQVPIsPEPLQRP
0 1 K121-u LQRPEMLkEETRSSA
0 10 K186-u VQMLVEGkEEGPAAW
0 6 K213-u GPQKDELkSFILQkY
0 26 K219-u LkSFILQkYMMVDSA
0 3 K230-u VDSAEDQkIHRPMAP
0 1 S254-gl YIDNQVVstkGERFK
0 1 T255-gl IDNQVVstkGERFKD
0 40 K256-u DNQVVstkGERFKDV
0 9 K272-u NPEAEEMkAtyINLk
0 3 T274-p EAEEMkAtyINLkPA
0 40 Y275-p AEEMkAtyINLkPAR
0 15 K279-u kAtyINLkPARKYRF
  mouse

 
K82 IIGDMMQKLSVQLSD
F110 VQGQVPIFPETPRQA
- gap
K183-u VHMLVEGkEEGPPGW
K210-u GPQKDDLkSFILQkY
K216-u LkSFILQkYMMVDRA
K227-u VDRAEDQkTHRPMAP
S251 YIDNQVVSTkGERFK
T252 IDNQVVSTkGERFKD
K253-u DNQVVSTkGERFKDV
K269-u NPEAEEMkATyINLk
T271 EAEEMkATyINLkPA
Y272-p AEEMkATyINLkPAR
K276-u kATyINLkPARKYRF
Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.